{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:44:05Z","timestamp":1783442645060,"version":"3.54.6"},"reference-count":25,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:sec><jats:title>Context:<\/jats:title><jats:p>Targeted secretion inhibitors (TSIs), a new class of recombinant biotherapeutic proteins engineered from botulinum toxin, represent a novel approach for treating diseases with excess secretion. They inhibit hormone secretion from targeted cell types through cleavage of SNARE (soluble N-ethylmaleimide-sensitive factor-activating protein receptor) proteins. qGHRH-LHN\/D is a TSI targeting pituitary somatotroph through binding to the GHRH-receptor and cleavage of the vesicle-associated membrane protein (VAMP) family of SNARE proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Our objective was to study SNARE protein expression in pituitary adenomas and to inhibit GH secretion from somatotropinomas using qGHRH-LHN\/D.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p>We analyzed human pituitary adenoma analysis for SNARE expression and response to qGHRH-LHN\/D treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting:<\/jats:title><jats:p>The study was conducted in University Hospitals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients:<\/jats:title><jats:p>We used pituitary adenoma samples from 25 acromegaly and 47 nonfunctioning pituitary adenoma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome:<\/jats:title><jats:p>Vesicle-SNARE (VAMP1\u20133), target-SNARE (syntaxin1, SNAP-23, and SNAP-25), and GHRH-receptor detection with RT-qPCR, immunocytochemistry, and immunoblotting. Assessment of TSI catalytic activity on VAMPs and release of GH from adenoma cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>SNARE proteins were variably expressed in pituitary samples. In vitro evidence using recombinant GFP-VAMP2&amp;3 or pituitary adenoma lysates suggested sufficient catalytic activity of qGHRH-LHN\/D to degrade VAMPs, but was unable to inhibit GH secretion in somatotropinoma cell cultures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>SNARE proteins are present in human pituitary somatotroph adenomas that can be targeted by TSIs to inhibit GH secretion. qGHRH-LHN\/D was unable to inhibit GH secretion from human somatotroph adenoma cells. Further studies are required to understand how the SNARE proteins drive GH secretion in human somatotrophs to allow the development of novel TSIs with a potential therapeutic benefit.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2013-2602","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T01:54:28Z","timestamp":1382579668000},"page":"E1918-E1926","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?"],"prefix":"10.1210","volume":"98","author":[{"given":"Edwin A.","family":"Garcia","sequence":"first","affiliation":[{"name":"Centre for Endocrinology (E.A.G., G.T., E.D.A., A.B.G., M.K.), William Harvey Research Institute, Department of Neurosurgery (I.S.), London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Trivellin","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology (E.A.G., G.T., E.D.A., A.B.G., M.K.), William Harvey Research Institute, Department of Neurosurgery (I.S.), London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena D.","family":"Aflorei","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology (E.A.G., G.T., E.D.A., A.B.G., M.K.), William Harvey Research Institute, Department of Neurosurgery (I.S.), London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Powell","sequence":"additional","affiliation":[{"name":"The National Hospital for Neurology and Neurosurgery (M.P., J.G.), University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Grieve","sequence":"additional","affiliation":[{"name":"The National Hospital for Neurology and Neurosurgery (M.P., J.G.), University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Alusi","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute (G.A., B.S.), Barts, and The London School of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Pobereskin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery (L.P.), Derriford Hospital, Derriford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Shariati","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute (G.A., B.S.), Barts, and The London School of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cudlip","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery (S.C.), John Radcliffe Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Roncaroli","sequence":"additional","affiliation":[{"name":"Division of Brain Sciences (F.R., N.M.), \u201cJohn Fulcher\u201d Laboratory, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Division of Brain Sciences (F.R., N.M.), \u201cJohn Fulcher\u201d Laboratory, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology (E.A.G., G.T., E.D.A., A.B.G., M.K.), William Harvey Research Institute, Department of Neurosurgery (I.S.), London, United Kingdom"},{"name":"Oxford Centre for Diabetes (A.B.G.), Endocrinology, and Metabolism, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Harper","sequence":"additional","affiliation":[{"name":"Syntaxin Ltd (E.A.H.), Abingdon, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology (E.A.G., G.T., E.D.A., A.B.G., M.K.), William Harvey Research Institute, Department of Neurosurgery (I.S.), London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615005079600_B1","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1210\/jcem.87.7.8631","article-title":"Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?","volume":"87","author":"Costa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615005079600_B2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0029-1239522","article-title":"Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity","volume":"42","author":"Elias","year":"2010","journal-title":"Horm Metab Res"},{"key":"2020071615005079600_B3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3171\/jns.2002.97.2.0287","article-title":"Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly","volume":"97","author":"Espinosa-de-los-Monteros","year":"2002","journal-title":"J Neurosurg"},{"key":"2020071615005079600_B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2265.2006.02430.x","article-title":"Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status","volume":"64","author":"Espinosa-de-los-Monteros","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615005079600_B5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000095532","article-title":"Quality of life in acromegaly","volume":"83","author":"Webb","year":"2006","journal-title":"Neuroendocrinology"},{"key":"2020071615005079600_B6","first-page":"2958","article-title":"Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs","volume":"85","author":"Herman-Bonert","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615005079600_B7","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071615005079600_B8","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1210\/jc.2003-030518","article-title":"Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm","volume":"88","author":"Clemmons","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615005079600_B9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03033931","article-title":"Botulinum neurotoxin\u2014from laboratory to bedside","volume":"9","author":"Foster","year":"2006","journal-title":"Neurotox Res"},{"key":"2020071615005079600_B10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/362318a0","article-title":"SNAP receptors implicated in vesicle targeting and fusion","volume":"362","author":"S\u00f6llner","year":"1993","journal-title":"Nature"},{"key":"2020071615005079600_B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"2020071615005079600_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2958.1994.tb00396.x","article-title":"Mechanism of action of tetanus and botulinum neurotoxins","volume":"13","author":"Montecucco","year":"1994","journal-title":"Mol Microbiol"},{"key":"2020071615005079600_B13","article-title":"The targeted secretion inhibitor (TSI), SXN101959, activates the rat GHRH receptor, internalises into GH3 cells stably expressing this receptor and cleaves vesicle associated membrane protein 2 (VAMP2)","volume":"9","author":"Cadd","year":"2011","journal-title":"Proc Br Pharmacolog Soc"},{"key":"2020071615005079600_B14","article-title":"N-terminal truncation of the qGHRH(1\u201340) targeting domain of the targeted secretion inhibitor (TSI) SXN101959 ablates its ability to activate the GHRH receptor, internalise into cells and cleave vesicle associated membrane protein 3 (VAMP3)","volume":"33","author":"Harper","year":"2012","journal-title":"Endocrine Rev"},{"key":"2020071615005079600_B15","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1172\/JCI63232","article-title":"A botulinum toxin-derived targeted secretion inhibitor downregulates the GH\/IGF1 axis","volume":"122","author":"Somm","year":"2012","journal-title":"J Clin Invest"},{"key":"2020071615005079600_B16","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1210\/en.2012-2175","article-title":"GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats","volume":"154","author":"Leggett","year":"2013","journal-title":"Endocrinology"},{"key":"2020071615005079600_B17","article-title":"The targeted secretion inhibitor (TSI) SXN101959 produces dose-dependent inhibition of pulsatile growth hormone secretion in male rats after intravenous administration","volume":"33","author":"Harper","year":"2012","journal-title":"Endocrine Rev"},{"key":"2020071615005079600_B18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study","volume":"97","author":"Ram\u00edrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615005079600_B19","doi-asserted-by":"crossref","first-page":"16755","DOI":"10.1016\/S0021-9258(18)66630-X","article-title":"Biosynthesis, glycosylation, movement through the Golgi system, and transport to lysosomes by an N-linked carbohydrate-independent mechanism of three lysosomal integral membrane proteins","volume":"261","author":"Barriocanal","year":"1986","journal-title":"J Biol Chem"},{"key":"2020071615005079600_B20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-0115(97)01017-3","article-title":"Botulinum neurotoxin F, a VAMP-specific endopeptidase, inhibits Ca(2+)-stimulated GH secretion from rat pituitary cells","volume":"71","author":"Jacobsson","year":"1997","journal-title":"Regul Pept"},{"key":"2020071615005079600_B21","doi-asserted-by":"crossref","first-page":"G1100","DOI":"10.1152\/ajpgi.00164.2004","article-title":"Agonist-induced polarized trafficking and surface expression of the adenosine 2b receptor in intestinal epithelial cells: role of SNARE proteins","volume":"287","author":"Wang","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2020071615005079600_B22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2337\/diabetes.51.5.1425","article-title":"Modulation of L-type Ca(2+) channels by distinct domains within SNAP-25","volume":"51","author":"Ji","year":"2002","journal-title":"Diabetes"},{"key":"2020071615005079600_B23","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1074\/jbc.M313592200","article-title":"Syntaxin 1A regulates ENaC channel activity","volume":"279","author":"Condliffe","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071615005079600_B24","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.bbrc.2005.07.195","article-title":"SNARE-mediated trafficking of \u03b15\u03b21 integrin is required for spreading in CHO cells","volume":"335","author":"Skalski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071615005079600_B25","article-title":"SXN101959, a targeted secretion inhibitor, has the same relative potency compared to GHRH(1\u201344) at GHRH receptors (GHRH-R) of rat, human and macaque","volume":"9","author":"Elliott","year":"2011","journal-title":"Proc Br Pharmacolog Soc"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/12\/E1918\/11127756\/jcem1918.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/12\/E1918\/11127756\/jcem1918.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:08:59Z","timestamp":1646910539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/12\/E1918\/2833382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-2602","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,1]]}}}